Adimmune Corp
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops Adim… Read more
Adimmune Corp (4142) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.073x
Based on the latest financial reports, Adimmune Corp (4142) has a cash flow conversion efficiency ratio of -0.073x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-355.08 Million) by net assets (NT$4.85 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Adimmune Corp - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Adimmune Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Adimmune Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adimmune Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CviLux Corp
TW:8103
|
0.054x |
|
RAJAF
OTCQB:RAJAF
|
8.352x |
|
Smart Eye AB
ST:SEYE
|
0.002x |
|
Tropicana Corporation Bhd
KLSE:5401
|
-0.058x |
|
Lotus Resources Ltd
AU:LOT
|
0.006x |
|
Klaveness Combination Carriers ASA
OL:KCC
|
0.060x |
|
Shanghai Xintonglian Packaging Co Ltd
SHG:603022
|
0.007x |
|
Nippon Chemi-Con Corporation
MU:NCZ
|
N/A |
Annual Cash Flow Conversion Efficiency for Adimmune Corp (2007–2024)
The table below shows the annual cash flow conversion efficiency of Adimmune Corp from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.56 Billion | NT$668.48 Million | 0.120x | +177.82% |
| 2023-12-31 | NT$5.78 Billion | NT$-892.35 Million | -0.154x | -246.22% |
| 2022-12-31 | NT$6.54 Billion | NT$-291.96 Million | -0.045x | +40.28% |
| 2021-12-31 | NT$6.43 Billion | NT$-480.52 Million | -0.075x | -121.33% |
| 2020-12-31 | NT$6.63 Billion | NT$2.32 Billion | 0.350x | +630.21% |
| 2019-12-31 | NT$3.83 Billion | NT$-252.72 Million | -0.066x | +79.62% |
| 2018-12-31 | NT$1.86 Billion | NT$-601.74 Million | -0.324x | -11178.96% |
| 2017-12-31 | NT$2.35 Billion | NT$6.87 Million | 0.003x | +101.17% |
| 2016-12-31 | NT$3.09 Billion | NT$-773.53 Million | -0.250x | -146.38% |
| 2015-12-31 | NT$3.68 Billion | NT$-373.82 Million | -0.101x | -8.59% |
| 2014-12-31 | NT$4.47 Billion | NT$-417.35 Million | -0.093x | +46.82% |
| 2013-12-31 | NT$3.24 Billion | NT$-568.64 Million | -0.176x | -60.56% |
| 2012-12-31 | NT$3.74 Billion | NT$-409.48 Million | -0.109x | -34.00% |
| 2011-12-31 | NT$3.60 Billion | NT$-293.77 Million | -0.082x | -164.23% |
| 2010-12-31 | NT$4.06 Billion | NT$516.39 Million | 0.127x | -20.26% |
| 2009-12-31 | NT$3.77 Billion | NT$600.42 Million | 0.159x | +472.28% |
| 2008-12-31 | NT$3.17 Billion | NT$-135.69 Million | -0.043x | -363.61% |
| 2007-12-31 | NT$1.92 Billion | NT$31.26 Million | 0.016x | -- |